Yes, Darvocet is a narcotic. It contains propoxyphene, a synthetic opioid that acts on the same brain receptors as other narcotic painkillers. The U.S. Drug Enforcement Administration classified it as a Schedule IV controlled substance, meaning it carried a recognized potential for misuse, abuse, and addiction. Darvocet was pulled from the U.S. market in November 2010 after the FDA determined it could cause dangerous heart rhythm problems even at normal prescribed doses.
What Darvocet Actually Contained
Darvocet was a combination pill with two active ingredients: propoxyphene napsylate (the opioid) and acetaminophen (the same pain reliever in Tylenol). It came in two strengths. Darvocet-N 50 contained 50 mg of propoxyphene and 325 mg of acetaminophen. Darvocet-N 100 contained 100 mg of propoxyphene and 650 mg of acetaminophen.
Propoxyphene is classified as a “centrally acting opiate analgesic,” meaning it works in the brain and spinal cord to reduce pain perception. Specifically, it activates mu-opioid receptors, the same receptors targeted by stronger narcotics like morphine and codeine. This is what made Darvocet effective for mild to moderate pain, and also what gave it the potential for dependence and misuse that comes with all opioids.
Why the FDA Pulled It From the Market
For years, concerns about propoxyphene’s safety simmered in the medical community. The drug was never considered particularly strong. Many clinicians questioned whether it worked much better than acetaminophen alone. But the real problem turned out to be the heart.
On November 19, 2010, the FDA formally recommended against continued prescribing of propoxyphene and asked manufacturers to voluntarily withdraw it from the U.S. market. The decision came after a new clinical study showed that propoxyphene, taken at standard therapeutic doses, caused significant changes in the heart’s electrical activity. Three key measurements on an electrocardiogram (ECG) were affected: the PR interval, the QRS complex, and the QT interval all became abnormally prolonged. These changes increase the risk of serious, potentially fatal heart rhythm disturbances.
At a daily dose of 600 mg (the high end of what some patients took), the QT interval shifted by nearly 30 milliseconds at steady state. At 900 mg, the shift reached 38 milliseconds. These are meaningful changes in cardiology. The FDA concluded that the safety risks of propoxyphene outweighed its benefits for pain relief, even at recommended doses. A related drug called Darvon, which contained propoxyphene without acetaminophen, was withdrawn at the same time.
How Propoxyphene Affected the Heart
The cardiac toxicity wasn’t just an overdose problem. Lab studies revealed that both propoxyphene and its main breakdown product in the body (norpropoxyphene) interfere with ion channels in heart cells. These channels control the electrical signals that keep the heart beating in rhythm. Propoxyphene blocks sodium channels in a way similar to local anesthetics, and its metabolite is roughly twice as potent at doing this. Both compounds also block potassium channels in the heart with roughly equal strength.
In animal studies, both substances slowed heart rate, reduced the force of heart contractions, and prolonged the time it takes for electrical signals to travel through the heart’s conduction system. The metabolite norpropoxyphene lingers in the body longer than propoxyphene itself, which means the cardiac effects could accumulate over days of regular use. This is part of why the FDA study found the most significant ECG changes at steady state, after 11 days of consistent dosing, rather than after a single dose.
Its Schedule IV Classification
Under the Controlled Substances Act, Darvocet was classified as Schedule IV. This placed it in the same regulatory tier as drugs like benzodiazepines and certain sleep medications. Schedule IV means the government recognized a lower potential for abuse compared to Schedule II opioids (like oxycodone) or Schedule III drugs, but still enough to warrant controlled prescribing and monitoring.
In practice, this lower scheduling made Darvocet easier to prescribe than stronger narcotics. Doctors sometimes chose it as a “milder” option for patients with moderate pain. That perception of relative safety, combined with the cardiac risks that weren’t fully understood until 2010, is part of why the withdrawal was so significant. Millions of prescriptions had been written over the decades it was available.
What Replaced Darvocet for Pain Management
Since Darvocet targeted mild to moderate pain, many of the alternatives that replaced it aren’t opioids at all. For acute pain, the CDC lists NSAIDs (like ibuprofen and naproxen, available as pills or topical creams), acetaminophen, and migraine-specific medications as frontline options.
For longer-lasting or chronic pain, the toolkit is broader. Certain antidepressants that affect pain signaling, particularly those in the SNRI and tricyclic classes, are commonly used. Anticonvulsant medications originally developed for seizures can help with nerve pain. Topical options like capsaicin cream and lidocaine patches provide localized relief without systemic opioid effects. If you were previously prescribed Darvocet and still need pain management, these categories represent where treatment has shifted since 2010.